{"id":154439,"date":"2021-01-27T14:55:29","date_gmt":"2021-01-27T19:55:29","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/vbl-therapeutics-treats-first-patient-in-phase-2-randomized-controlled-study-of-vb-201-in-covid-19-patients\/"},"modified":"2024-08-18T11:40:49","modified_gmt":"2024-08-18T15:40:49","slug":"vbl-therapeutics-treats-first-patient-in-phase-2-randomized-controlled-study-of-vb-201-in-covid-19-patients","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/vbl-therapeutics-treats-first-patient-in-phase-2-randomized-controlled-study-of-vb-201-in-covid-19-patients.php","title":{"rendered":"VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients"},"content":{"rendered":"<p><![CDATA[TEL AVIV, Israel, Jan.  27, 2021  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the dosing of the first patient in a randomized controlled Phase 2 study of the Company\u2019s proprietary investigational oral immune-modulator molecule, VB-201 for the treatment of COVID-19. The study will assess the ability of VB-201 to prevent clinical deterioration and reduce morbidity and mortality in patients with severe COVID-19.]]><\/p>\n<p>Go here to see the original:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2021\/01\/27\/2164946\/0\/en\/VBL-Therapeutics-Treats-First-Patient-in-Phase-2-Randomized-Controlled-Study-of-VB-201-in-COVID-19-Patients.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients\">VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Go here to see the original: VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/vbl-therapeutics-treats-first-patient-in-phase-2-randomized-controlled-study-of-vb-201-in-covid-19-patients.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-154439","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/154439"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=154439"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/154439\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=154439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=154439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=154439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}